Amendment No. 4 to Schedule 13D for Athira Pharma, Inc.

This filing details an amendment to a Schedule 13D for Athira Pharma, Inc. On December 18, 2025, Perceptive Life Sciences Master Fund, Ltd. and Perceptive Xontogeny Venture Fund II, LP entered into a Securities Purchase Agreement to acquire an aggregate of 1,319,026 shares of Common Stock at $6.35 per share, along with various warrants. The transaction, expected to close on December 23, 2025, is subject to customary closing conditions. Additionally, Athira Pharma entered into an agreement with Sermonix Pharmaceuticals, Inc. to license the development, manufacture, and commercialization of oral forms of lasofoxifene, issuing pre-funded warrants for 5,502,402 shares of Common Stock to Sermonix. Joseph Edelman, representing Perceptive Advisors LLC and its affiliated funds, reported beneficial ownership of approximately 13.7% of Athira Pharma's common stock, with the potential to acquire more shares through vested options.